CS
IOVA icon

Credit Suisse’s Iovance Biotherapeutics IOVA Stock Holding History

Credit Suisse’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$29.8M Sell
2,008,046
-806,270
-29% -$9.38M 0.03% 527
2023
Q4 		$22.9M Sell
2,814,316
-29,153
-1% -$153K 0.02% 627
2023
Q3 		$12.9M Buy
2,843,469
+49,345
+2% +$322K 0.01% 799
2023
Q2 		$19.7M Buy
2,794,124
+97,282
+4% +$696K 0.02% 680
2023
Q1 		$16.5M Buy
2,696,842
+31,262
+1% +$216K 0.02% 734
2022
Q4 		$17M Buy
2,665,580
+55,875
+2% +$436K 0.02% 725
2022
Q3 		$25M Sell
2,609,705
-28,597
-1% -$330K 0.03% 596
2022
Q2 		$29.1M Buy
2,638,302
+140,769
+6% +$1.84M 0.03% 567
2022
Q1 		$41.6M Buy
2,497,533
+60,717
+2% +$939K 0.04% 516
2021
Q4 		$46.5M Buy
2,436,816
+21,203
+0.9% +$467K 0.02% 682
2021
Q3 		$59.6M Buy
2,415,613
+3,410
+0.1% +$80.3K 0.03% 573
2021
Q2 		$62.8M Buy
2,412,203
+17,714
+0.7% +$460K 0.03% 577
2021
Q1 		$75.8M Buy
2,394,489
+2,368,369
+9,067% +$98.2M 0.04% 537
2020
Q4 		$1.21M Sell
26,120
-29,612
-53% -$1.18M ﹤0.01% 3190
2020
Q3 		$1.83M Sell
55,732
-22,494
-29% -$690K ﹤0.01% 2481
2020
Q2 		$2.15M Buy
78,226
+70,598
+926% +$2.32M ﹤0.01% 2337
2020
Q1 		$228K Sell
7,628
-1,417,880
-99% -$37.6M ﹤0.01% 3581
2019
Q4 		$39.5M Sell
1,425,508
-100,414
-7% -$2.28M 0.03% 676
2019
Q3 		$27.8M Sell
1,525,922
-44,384
-3% -$982K 0.02% 734
2019
Q2 		$38.5M Sell
1,570,306
-319,988
-17% -$4.82M 0.03% 569
2019
Q1 		$18M Buy
1,890,294
+421
+0% +$4.09K 0.02% 921
2018
Q4 		$16.7M Buy
1,889,873
+329,048
+21% +$3.17M 0.02% 886
2018
Q3 		$17.6M Buy
1,560,825
+529,511
+51% +$7.52M 0.02% 948
2018
Q2 		$13.2M Sell
1,031,314
-420,246
-29% -$6.14M 0.01% 1077
2018
Q1 		$24.5M Buy
1,451,560
+356,132
+33% +$5.39M 0.02% 749
2017
Q4 		$8.76M Buy
1,095,428
+1,021,734
+1,386% +$8.2M 0.01% 1370
2017
Q3 		$571K Buy
73,694
+47,143
+178% +$298K ﹤0.01% 3467
2017
Q2 		$196K Sell
26,551
-9,052
-25% -$57.5K ﹤0.01% 3625
2017
Q1 		$265K Buy
35,603
+1,351
+4% +$9.9K ﹤0.01% 3560
2016
Q4 		$238K Sell
34,252
-10,078
-23% -$69.3K ﹤0.01% 3747
2016
Q3 		$366K Sell
44,330
-2,690
-6% -$22.8K ﹤0.01% 3577
2016
Q2 		$381K Buy
47,020
+4,833
+11% +$30.4K ﹤0.01% 3572
2016
Q1 		$215K Sell
42,187
-1,191
-3% -$6.52K ﹤0.01% 3656
2015
Q4 		$335K Buy
43,378
+20,986
+94% +$146K ﹤0.01% 3632
2015
Q3 		$129K Sell
22,392
-1,722
-7% -$13.4K ﹤0.01% 4058
2015
Q2 		$221K Sell
24,114
-28,824
-54% -$322K ﹤0.01% 4171
2015
Q1 		$641K Buy
+52,938
New +$596K ﹤0.01% 3359

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Credit Suisse's IOVA Position: Q1 2024 in Review

Credit Suisse reduced its Iovance Biotherapeutics (IOVA) stake by 29% in Q1 2024, selling an estimated $9.38M and leaving 2,008,046 shares worth $29.8M. The position accounts for 0.03% of the portfolio, ranked #527.

Credit Suisse first reported a position in IOVA in Q1 2015 and has held it in 37 quarters since. The position peaked at $75.8M in Q1 2021. 273 funds tracked by Wall St. Rank hold IOVA as of Q1 2024.

  • Credit Suisse held 2,008,046 shares of Iovance Biotherapeutics worth $29.8M as of Q1 2024.
  • Credit Suisse sold 806,270 Iovance Biotherapeutics shares in Q1 2024, an estimated $9.38M.
  • Iovance Biotherapeutics made up 0.03% of Credit Suisse's portfolio in Q1 2024, its #527 holding.
  • Credit Suisse first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 37 quarters since.
  • Credit Suisse's Iovance Biotherapeutics position peaked at $75.8M in Q1 2021.
  • 273 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.